×

2000 Song BC, Suh DJ, Lee HC, Chung YH, Lee YS, Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32;803-806.

2003 Lee HC, Suh DJ, Ryu SH, Kim H, Shin JW, Lim YS, Chung YH, Lee YS. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B antigen loss or seroconversion. Gut 2003;52:177-1783.

2003 Lee HC, Suh DJ. Lamivudine therapy for decompensated liver cirrhosis related to hepatitis B virus infection. Intervirology 2003;46:388-393.

2004 Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Which patients with chronic hepatitis B are more likely to relapse after interferon-induced Hepatitis B e antigen loss in Korea? J Clin Gastroenterol 2004;38:124-129.

2005 Kim KM, Choi WB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Kor Med Sci 2005;20:821-8.

2006 LeeYS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-1391

2009 Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, LeeYS. Efficacy of entecavir in chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009;50:1064-1071